coadministered cagrilintide and semaglutide in adults with overweight or obesity New the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for (REDEFINE 1 phase 3a trial) Cagrilintide– for Overweight Diabetes (REDEFINE 2 phase 3a trial) We are all anxiously awaiting
We are all anxiously awaiting more research on the combination of cagrilintide and semaglutide (#ozempic #wegovy) which has been shown in global studies to induce very meaningful #weightloss. This study assessed the efficacy The next frontier in metabolic health: Cagrilintide Semaglutide and the evolving landscape of therapies Cagrilintide & Semaglutide in Overweight Adults (REDEFINE 1) NEJM Med Journal Club CagriSema: a novel dual pathway approach to target obesity and its complications
Pay in 4 interest-free payments of $5.75 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6


